Metformin use and its association with various outcomes in COVID-19 patients with diabetes mellitus: a retrospective cohort study in a tertiary care facility.

Publication date: Dec 01, 2024

Evidence shows that diabetes raises the probability of contracting COVID-19 and associated complications. We hypothesize that metformin, being pleiotropic, may improve COVID-19 in diabetics. A retrospective cohort study was conducted with 421 COVID-19 patients with diabetes, hospitalized between 1st April 2020 and 31st March 2022 in a tertiary-care hospital. Patients with metformin or its combination constituted the study cohort (SC; n = 221), while other antidiabetics constituted the reference cohort (RC; n = 200). SC and RC were matched for mean age +/- SD (SC: 53. 3 +/- 5. 7 vs. RC: 54. 3 +/- 8. 2 years). The mean length of hospitalization (days) was significantly shorter in SC (9. 0 +/- 5. 7) than in RC (12. 7 +/- 6) (p 

Concepts Keywords
2years Aged
Covid COVID-19
Diabetes COVID-19
Drugs COVID-19 Drug Treatment
Hospitalization diabetes
Diabetes Mellitus
Diabetes Mellitus, Type 2
Female
fibrin fragment D
Hospitalization
Humans
Hypoglycemic Agents
Hypoglycemic Agents
Length of Stay
Male
Metformin
Metformin
metformin
Middle Aged
mortality
Retrospective Studies
SARS-CoV-2
SARS-CoV-2
Tertiary Care Centers

Semantics

Type Source Name
drug DRUGBANK Metformin
disease MESH COVID-19
disease MESH diabetes mellitus
disease IDO facility
disease MESH complications
disease MESH Diabetes Mellitus Type 2

Original Article

(Visited 1 times, 1 visits today)